Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).

Authors
Type
Published Article
Journal
Clinical endocrinology
Publication Date
Volume
70
Issue
1
Pages
124–128
Identifiers
DOI: 10.1111/j.1365-2265.2008.03345.x
PMID: 19128368
Source
Medline
License
Unknown

Abstract

In these obese patients with PCOS, metformin maintained the weight loss and enhanced the metabolic and biochemical parameters achieved by treatment with rimonabant, compared to 6 months of metformin treatment alone.

Statistics

Seen <100 times